Safety of Intravenous Autologous Bone Marrow-Derived Mesenchymal Cell Transplantation in 5 Patients With Reduced Left Ventricular Ejection Fraction

Background: Although intracardiac injection or intracoronary delivery of mesenchymal stem cells (MSCs) has been reported, there have been few studies on the intravenous injection of MSCs, particularly in Japan. Methods and Results: Five patients with left ventricular ejection fraction (LVEF) ≤45% re...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Yukihito, Kuragaichi, Takashi, Saga, Shunsuke, Nakayama, Hiroyuki, Obata, Tomoe, Watanabe, Mitsumasa, Fujikura, Kie, Watanabe, Masatoki, Hata, Ken-ichiro, Ohgushi, Hajime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Circulation Society 2021
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423613/
https://www.ncbi.nlm.nih.gov/pubmed/34568634
http://dx.doi.org/10.1253/circrep.CR-21-0091
Descripción
Sumario:Background: Although intracardiac injection or intracoronary delivery of mesenchymal stem cells (MSCs) has been reported, there have been few studies on the intravenous injection of MSCs, particularly in Japan. Methods and Results: Five patients with left ventricular ejection fraction (LVEF) ≤45% received 1.0×10(8) MSCs intravenously. The procedure did not induce significant changes in vital signs. One patient had an elevated body temperature after 1 day, but recovered spontaneously. Laboratory tests remained normal for 1 month after cell delivery. Computed tomography was performed after 1–2 years, and there was no evidence of malignancy. Conclusions: In this pilot study of patients with reduced LVEF, intravenous MSC delivery had no adverse effects.

Ejemplares similares